Indication
For treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Medicine details
- Medicine name:
- fezolinetant (Veoza)
- SMC ID:
- SMC2898
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Resubmission
- Publication due date:
- 13 July 2026
- SMC meeting date:
- 02 June 2026
- Patient group submission deadline:
- 05 May 2026